Skip to main content
Fig. 1 | Cardio-Oncology

Fig. 1

From: A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

Fig. 1

Schematic of circulatory miRNAs. A Exosomal microvesicles can be released by several types of cell within the cardiovascular system and enter into the circulatory system. B The biogenesis of miRNAs: i) biogenesis begins in the cell nucleus with the transcription of the DNA into large pri-miRNAs which are cleaved by the Drosha enzyme into pre-miRNAs that can be transported into the cytoplasm, ii) The Dicer enzyme cleaves the pre-miRNA into immature miRNA duplexes of 21 to 25 nucleotides and then to a single stranded mature miRNA, iii) miRNAs can be incorporated into a RNA-induced silencing complex (RISC) which can bind or partially-bind to mRNA and inhibit translation or promote degradation, iv) pre-miRNAs and mature miRNAs can be secreted from the cell in exosomes or lipid vesicles as well as bound to RNA-binding proteins and lipoproteins. C microvesicles can enter the circulatory system where they can be detected from blood samples (and other bodily fluids) for the purposes of prognosis, diagnosis and as therapeutic targets

Back to article page